Escherichia coli (E. Coli) is the most popular cell extract source for cell-free expression systems. However, extracts from wheat germ, rabbit reticulocytes or insect cells are also commonly used. Other mammalian cell lines are also more recently used for cell-free protein biosynthesis. Since they present different properties and advantages, the source of cell extract will be selected according to the properties of the protein to synthesize, such as the need for post-translational modifications, and other constraints, like yield, costs or convenience of cell extract preparation (Carlson et al., 2012; Casteleijn et al., 2013, Zemella et al., 2015).
0 Comments Click here to read/write comments
Topics: Cell-free technology
Although traditional cell-free protein synthesis is only considered appropriate for small scale protein production, technological breakthroughs made since the turn of the century have drastically accelerated the development of this production platform, making it now suitable at the industrial scale. Previous limitations of the cell-free technology have been addressed: it is now scalable, consistent, robust and cost-effective (Zawada et al., 2011). Yields have been increased, the use of expensive reagents is no longer necessary, reactions lengthened, and reaction scales increased (Carlson et al., 2012), all of which contribute to making cell-free technology an interesting and efficient platform for industrial applications.
0 Comments Click here to read/write comments
Topics: Cell-free technology
The E. coli expression system is well-established, and its ability to produce large amounts of protein in a limited time is advantageous when compared to other expression systems, such as eukaryotic systems for which 3 or 4 weeks lead time are required.
0 Comments Click here to read/write comments
Topics: Cell-free technology
Cell-free expression system offers advantages over cell-based expression systems for difficult-to-express proteins, not only for membrane proteins, but also for proteins with multiple disulfide bonds or cytotoxic proteins, for example.
0 Comments Click here to read/write comments
Topics: Cell-free technology
Synthelis will attend the 3rd edition of the “Colloque POLEPHARMA Bioproduction” which takes place in Tours, December 20th.
0 Comments Click here to read/write comments
Topics: Cell-free technology, Proteins
In protein manufacturing, membrane proteins are well known to be challenging to produce in a functional form. SYNTHELIS’ patented cell-free technology allows customized expression and characterization of active proteins integrated in proteoliposomes. Membrane proteins are embedded directly into liposomes during the cell-free synthesis process allowing the proper folding of the protein. Following protein production, SYNTHELIS conducts quality controls to validate the target protein in terms of activity and structure.
0 Comments Click here to read/write comments
Topics: Cell-free technology, Proteins
0 Comments Click here to read/write comments
Topics: Cell-free technology, Proteins, Biotech
0 Comments Click here to read/write comments
Topics: Cell-free technology, Proteins, Biotech
